|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 6S. Outcome and EBOV Genome Equivalents in Plasma and CSF from Experiment 1** | | | | | | | | | | | | |
| Treatment | Animal ID | *In vivo* outcome (day) | Plasma EBOV (GE/mL) by study day | | | | | | | | | CSF at necropsy (GE/mL) |
| 3 | 6 | 7 | 8 | 9 | 10 | 12 | 21 | 29 |
| Saline Control | 1 | D8 | <LOQ | 1.1E8 | NT | 1.0E8 | NT | NT | NT | NT | NT | NT |
| 2 | D7 | 2.3E6 | 7.5E9 | 1.6E10 | NT | NT | NT | NT | NT | NT | 5.8E7 |
| EI: Irrelevant Tc hIgG control | 3 | D7 | <LOQ | 5.0E9 | 1.8E10 | NT | NT | NT | NT | NT | NT | 4.0E5 |
| 4 | D8 | 6.9E5 | 8.6E4 | NT | 4.1E8 | NT | NT | NT | NT | NT | NT |
| 5 | D7 | <LOQ | 1.4E9 | 5.2E9 | NT | NT | NT | NT | NT | NT | 1.5E10 |
| 6 | D8 | 7.9E5 | 6.1E9 | NT | 4.4E9 | NT | NT | NT | NT | NT | 5.9E7 |
| 7 | D8 | <LOQ | 4.8E9 | NT | 2.5E9 | NT | NT | NT | NT | NT | 4.4E6 |
| 8 | D7 | 1.4E5 | 4.2E10 | 7.9E10 | NT | NT | NT | NT | NT | NT | <LOQ |
| EI: SAB-139/V3-V4 | 9 | D8 | <LOQ | <LOQ | NT | NT | NT | NT | NT | NT | NT | NT |
| 10 | D9 | <LOQ | 7.7E6 | NT | NT | 2.6E10 | NT | NT | NT | NT | 2.4E5 |
| 11 | D12 | <LOQ | 1.6E5 | NT | NT | NT | 1.7E8 | 2.1E10 | NT | NT | 2.3E9 |
| 12 | D12 | <LOQ | <LOQ | NT | NT | NT | 2.0E8 | 5.3E8 | NT | NT | 3.9E6 |
| 13 | S29 | <LOQ | 4.5E5 | NT | NT | NT | <LOQ | NT | <LOQ | <LOQ | <LOQ |
| 14 | S29 | <LOQ | 5.9E5 | NT | NT | NT | <LOQ | NT | <LOQ | <LOQ | 7.4E8 |

Abbreviations: CSF, cerebrospinal fluid; D, died (day); EI, early intervention (treatment initiated on day 1 postexposure); GE, genome equivalents; ID, identification number; S, survived (day 29 postexposure); LOQ, limit of quantification; NT, not tested; Tc hIgG, transchromosomic human Immunoglobulin G.